Wednesday, August 12, 2026
RSS

Markets & Money

Nasdaq's Strategic Acquisition of LeveL Markets: Implications for 24/7 Trading

Nasdaq's acquisition of LeveL Markets signals a major shift towards extended trading hours, reshaping market infrastructure.

By Marcus Rivera • August 11, 2026
Pharmaceutical

AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades

AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adjustments.

Sarah Chen • Aug 11
Pharmaceutical

Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment

Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor interest.

James McAllister • Aug 11
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Markets & Money

H&R REIT's C$6.7 Billion Take-Private: A Game Changer for Canadian Real Estate?

H&R REIT's C$6.7 billion acquisition could reshape the Canadian commercial real estate landscape.

Marcus Rivera • Aug 11, 2026
Tech

Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape

Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst evolving private eq…

Sarah Chen • Aug 11, 2026
Pharmaceutical

PDS Biotech Shifts Focus to PDS0301: Implications for Investors

PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.

James McAllister • Aug 11, 2026
Pharmaceutical

Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition

Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and com…

Marcus Rivera • Aug 10, 2026
Pharmaceutical

Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences

Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare disease pipeline.

Sarah Chen • Aug 10, 2026
Pharmaceutical

AbCellera Biologics Stock Soars on Positive Phase 2 Trial Results

AbCellera's shares surged 30.3% after positive Phase 2 trial results for its innovative antibody, ABCL635.

James McAllister • Aug 10, 2026
Tech

Teledyne's $1.1B Deal for Varex Imaging: Analyzing Market Implications

Teledyne's acquisition of Varex Imaging boosts shares and reshapes the medical imaging landscape.

Marcus Rivera • Aug 10, 2026
Pharmaceutical

Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences

Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indicating potential reve…

Sarah Chen • Aug 10, 2026
Pharmaceutical

Jazz Pharmaceuticals' $1.32B Acquisition: What Investors Need to Know

Jazz Pharmaceuticals is set to acquire Actio Biosciences for $1.32 billion, a move that could reshape its market positio…

James McAllister • Aug 10, 2026